Zevra Therapeutics, a Rare Disease Therapeutics Company, Files Preliminary Proxy

Stock Information for KemPharm Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About KemPharm Inc

Zevra Therapeutics Reiterates Commitment to Rare Disease Community as New Corporate Council Member of the National Organization for Rare Disorders (NORD)
Zevra Therapeutics to Report Fourth Quarter and Full-Year 2022 Results
Zevra Therapeutics Announces Arimoclomol Research Featured in Two Poster Presentations at the 19th Annual WORLDSymposium(TM) 2023
Zevra Therapeutics Announces Two Abstracts Accepted for Presentation at the 19th Annual WORLDSymposium(TM) 2023
CORRECTION - KemPharm Announces Corporate Name Change to Zevra Therapeutics
KemPharm Announces Corporate Name Change to Zevra Therapeutics
KemPharm Enhances Senior Management Team
KemPharm Issues Letter to Shareholders

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.